A New Weapon Against Amputation: Lakewood-Amedex Advances Resistance-Evading Gel

SARASOTA, Fla. – September 18, 2026 — Every twenty seconds, a diabetic patient somewhere in the world undergoes a lower-limb amputation. Up to 85% of these life-altering surgeries begin as a seemingly manageable issue: an infected diabetic foot ulcer. It is a cascading failure of human health, exacerbated by the growing inability of traditional antibiotics to clear infections in compromised tissue. Today, a clinical-stage biotechnology company took a critical step toward shifting this grim paradigm.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) announced it has secured central and site-level Institutional Review Board (IRB) approvals, confirming clinical site readiness for a Phase 2a trial of its lead asset, Nu-3. The proprietary topical gel is designed to treat mildly infected diabetic foot ulcers (iDFU) using a novel mechanism that physically destroys bacterial cells, sidestepping the escalating crisis of antimicrobial resistance (AMR).

Cracking the Superbug Defense

To understand the significance of this clinical milestone, one must look at the physiological battlefield of a diabetic foot infection. Current clinical practice guidelines generally favor short courses of oral systemic antibiotics for mild infections. However, treating a diabetic foot ulcer with an oral pill is a physiological uphill battle. Diabetic patients frequently suffer from ischemic, microvascularly compromised extremities. Systemic drugs simply cannot reach the wound bed in therapeutic concentrations. Instead, they circulate systemically, driving gut dysbiosis, risking severe secondary infections, and fueling the broader superbug crisis.

The alternative being tested by Lakewood-Amedex belongs to a novel chemical family called Bisphosphocins. Rather than attempting to inhibit bacterial metabolic pathways or protein synthesis—mechanisms that pathogens rapidly mutate to evade—the active ingredient in Nu-3 physically destabilizes the bacterial cell membrane. It is a biophysical attack rather than a biochemical one. Independent scientific evaluations note that this concentration- and pH-dependent membrane disruption typically induces cell rupture in under 60 seconds. Furthermore, unlike traditional oral or intravenous antibiotics that fail against metabolically dormant bacteria hidden within protective biofilms, this topical gel is engineered to penetrate and disrupt established bacterial colonies.

The barrier to resistance is remarkably high. In preclinical continuous 21-day serial passage assays, the minimum inhibitory concentration (MIC) of Nu-3 remained completely flat against MRSA, while a standard comparator drug saw resistance spike by more than 600-fold. This resistance-evading profile directly answers federal mandates set forth by the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB), positioning the therapy as a potential public health asset in the broader war against AMR.

The Clinical Pivot: Rethinking Limb Preservation

The newly approved Phase 2a trial is a prospective, randomized, multi-center, single-blind study that will evaluate three distinct concentrations of the Nu-3 gel applied twice daily over a 14-day period. By testing multiple dose arms in adult subjects with Type 1 or Type 2 diabetes presenting with mildly infected chronic ulcers, the company is executing a classic de-risking maneuver. Establishing clear dose-response dynamics now will inform the architecture of a much larger, capital-intensive Phase 2b trial down the road.

"Together, these milestones mark another significant step forward in the company's clinical development strategy to address the urgent medical need for new treatments for drug-resistant wound infections," noted Dr. Thomas Balzer, Chief Medical Officer of Lakewood-Amedex. "With the guidance of our Study Chair, the world-renowned expert Dr. David G. Armstrong, we are well-positioned to evaluate how Nu-3 can potentially improve patient outcomes in the management of iDFU, a condition that impacts millions of lives worldwide and remains a leading cause of lower-limb amputations."

The involvement of Dr. Armstrong—a distinguished professor and founding director of the Southwestern Academic Limb Salvage Alliance—signals a strong alignment with modern podiatric philosophies. Modern limb preservation champions the interdisciplinary "Toe and Flow" model, which treats the diabetic foot much like a cancer that can be put into remission. Because diabetic neuropathy robs patients of the "gift of pain," mild infections can progress silently into deep tissue destruction and bone infection. A fast-acting, non-resistant topical agent applied at the earliest signs of mild infection represents an essential missing tool to prevent this rapid deterioration.

The Micro-Cap High-Wire Act

To understand the modern biotech landscape is to understand the paradox of the micro-cap innovator. On one hand, you have a lead asset targeting a multi-billion-dollar global wound care market, backed by highly cited clinician-scientists. On the other hand, Lakewood-Amedex trades with a market capitalization hovering between $4 million and $5.5 million.

A look at the company's latest Form 10-Q filings from mid-2026 reveals the stark reality of clinical-stage development. Following a strategic recapitalization earlier this year—which included a $7.5 million Series C preferred financing and significant debt restructuring—the firm sits on approximately $4.6 million in total liquid capital. With normalized quarterly operational burns ranging up to $1 million, and roughly $1.2 million committed to contract research and manufacturing organizations for this specific trial, the financial math is unforgiving.

The current runway extends into early 2027, accompanied by a standard auditor's going-concern warning. This sequencing of a smaller Phase 2a trial is therefore not just a clinical necessity, but a financial survival tactic. It is a binary event. The capital on hand is sufficient to execute and complete this proof-of-concept trial, but not enough to fund follow-on pivotal studies. Management is racing against its burn rate to produce compelling human data that can trigger non-dilutive licensing partnerships or secure stronger equity financing.

A Blueprint for the Future of Wound Care

The stakes for this trial extend far beyond the balance sheet of a single Florida-based biotechnology firm. Historically, clinical guidelines have suggested against the routine use of topical antibiotics because legacy products failed to demonstrate definitive superiority in robust, late-stage trials. Consequently, a topical agent demonstrating clear clinical resolution and microbiologic clearance would solve a massive gap in standard care.

In earlier exploratory trials using an aqueous solution formulation, patients receiving the active therapy achieved a 65.5% reduction in ulcer surface area at Day 14, compared to just 29.9% in the placebo control group. Microbiological clearance followed a similarly promising trend.

If the upcoming Phase 2a gel trial replicates or exceeds these earlier signals, it will validate the Bisphosphocin platform as a viable commercial and clinical entity. More importantly, it will offer millions of diabetic patients a frontline defense against the insidious progression of foot ulcers. In the intersection of human impact and clinical innovation, providing a simple, resistance-proof topical gel could be the exact intervention required to keep patients walking, out of the hospital, and free from the devastating finality of amputation.